Loading...
•
Dec 31, 2021
Scynexis Q4 2021 Earnings Report
SCYNEXIS reported financial results for the fourth quarter and full year ended on December 31, 2021.
Key Takeaways
SCYNEXIS reported fourth-quarter results with BREXAFEMME generating net product revenue of $0.6 million. The company highlighted the approval and launch of BREXAFEMME and advancements in ibrexafungerp's development across multiple indications.
BREXAFEMME achieved net revenues of $0.6 million in Q4 2021.
BREXAFEMME was prescribed by over 1,600 healthcare providers in Q4 2021.
Commercial insurance covered BREXAFEMME for over 81 million commercially-insured lives by the end of 2021.
SCYNEXIS is initiating MARIO, a global Phase 3 study to evaluate ibrexafungerp as an oral step-down treatment for invasive candidiasis (IC).
Scynexis
Scynexis
Forward Guidance
SCYNEXIS expects to enlarge the prescriber base, expand payer coverage, and grow BREXAFEMME revenues, file a supplemental New Drug Application (sNDA) in recurrent vulvovaginal candidiasis (rVVC) and receive approval for this label expansion by the end of 2022 and SCYNEXIS has a projected cash runway into the second quarter of 2023.
Positive Outlook
- Enlarging the prescriber base
- Expanding payer coverage
- Growing BREXAFEMME revenues
- Filing a supplemental New Drug Application (sNDA) in recurrent vulvovaginal candidiasis (rVVC)
- Receiving approval for this label expansion by the end of 2022